Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors

• Published in: Heart (British Cardiac Society) Vol. 104; no. 24; pp. 1995 - 2002
• Main Authors: Dobbin, Stephen J H, Cameron, Alan C, Petrie, Mark C, Jones, Robert J, Touyz, Rhian M, Lang, Ninian N
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.12.2018
• Subjects: Angiogenesis Inhibitors - adverse effects; Animals; Cancer therapies; Cardiotoxicity; Heart Diseases - chemically induced; Heart Diseases - diagnosis; Heart Diseases - physiopathology; Heart Diseases - therapy; Hemodynamics - drug effects; Humans; Hypertension - chemically induced; Hypertension - diagnosis; Hypertension - physiopathology; Hypertension - therapy; Kinases; Prognosis; Protein Kinase Inhibitors - adverse effects; Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors; Risk Assessment; Risk Factors; Signal Transduction - drug effects; Systematic review; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Ventricular Function, Left - drug effects; heart failure; cardiac risk factors and prevention; translational cardiovascular science; pharmacology
• ISSN: 1355-6037; 1468-201X
• DOI: 10.1136/heartjnl-2018-313726

Clinical outcomes for patients with a wide range of malignancies have improved substantially over the last two decades. Tyrosine kinase inhibitors (TKIs) are potent signalling cascade inhibitors and have been responsible for significant advances in cancer therapy. By inhibiting vascular endothelial growth factor receptor (VEGFR)-mediated tumour blood vessel growth, VEGFR-TKIs have become a mainstay of treatment for a number of solid malignancies. However, the incidence of VEGFR-TKI-associated cardiovascular toxicity is substantial and previously under-recognised. Almost all patients have an acute rise in blood pressure, and the majority develop hypertension. They are associated with the development of left ventricular systolic dysfunction (LVSD), heart failure and myocardial ischaemia and can have effects on myocardial repolarisation. Attention should be given to rigorous baseline assessment of patients prior to commencing VEGFR-TKIs, with careful consideration of baseline cardiovascular risk factors. Baseline blood pressure measurement, ECG and cardiac imaging should be performed routinely. Hypertension management currently follows national guidelines, but there may be a future role forendothelin-1 antagonism in the prevention or treatment of VEGFR-TKI-associated hypertension. VEGFR-TKI-associated LVSD appears to be independent of dose and is reversible. Patients who develop LVSD and heart failure should be managed with conventional heart failure therapies, but the role of prophylactic therapy is yet to be defined. Serial monitoring of left ventricular function and QT interval require better standardisation and coordinated care. Management of these complex patients requires collaborative, cardio-oncology care to allow the true therapeutic potential from cancer treatment while minimising competing cardiovascular effects.